Center for Primary Health Care Research, Lund University, Region Skåne, Lund, Sweden.
Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nat Commun. 2020 Jun 24;11(1):3191. doi: 10.1038/s41467-020-17028-4.
Phosphodiesterase-5 (PDE5) inhibitors are suggested to have anti-tumor effects and to inhibit surgery-induced immunosuppression. We aimed to explore whether post-diagnostic use of PDE5 inhibitors was associated with a better prognosis among male patients with colorectal cancer (CRC) and the role of open surgery in the association. Here we show that post-diagnostic use of PDE5 inhibitors is associated with a decreased risk of CRC-specific mortality (adjusted HR = 0.82, 95% CI 0.67-0.99) as well as a decreased risk of metastasis (adjusted HR = 0.85, 95% CI 0.74-0.98). Specifically, post-operative use of PDE5 inhibitors has a strong anti-cancer effect. The reduced risk of metastasis is mainly due to distant metastasis but not regional lymphatic metastasis. PDE5 inhibitors have the potential to be an adjuvant drug for patients with CRC to improve prognosis, especially those who have undergone open surgery.
磷酸二酯酶-5（PDE5）抑制剂具有抗肿瘤作用，并能抑制手术引起的免疫抑制。我们旨在探讨诊断后使用 PDE5 抑制剂是否与结直肠癌（CRC）男性患者的预后改善相关，以及开放性手术在这种关联中的作用。我们在这里表明，诊断后使用 PDE5 抑制剂与 CRC 特异性死亡率降低相关（调整后的 HR=0.82，95%CI 0.67-0.99），以及转移风险降低相关（调整后的 HR=0.85，95%CI 0.74-0.98）。具体来说，术后使用 PDE5 抑制剂具有很强的抗癌作用。转移风险的降低主要是由于远处转移而不是区域淋巴结转移。PDE5 抑制剂有可能成为 CRC 患者的辅助药物，以改善预后，特别是那些接受过开放性手术的患者。
Zotero 插件
